Overview Dividends

(CAH) Cardinal Health - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US14149Y1082

Pharmaceuticals, Medical Devices, Surgical Supplies, Laboratory Products

Health Care Distributors
Market Cap in USD: 48,826m

IPO / Inception: 1987-12-31
Return 12m vs S&P 500: 50.1%

EPS (Earnings per Share)

EPS CAGR: -44.58%
EPS Trend: 6.5%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 9.56%
Rev. Trend: 88.7%

Last SUE: 4.00
Qual. Beats: 1

Dividends

Dividend Yield	0.98%
Yield on Cost 5y	4.11%
Yield CAGR 5y	0.94%
Payout Consistency	93.5%
Payout Ratio	22.9%

Risk via 5d forecast
Volatility	23.1%
Value at Risk 5%th	33.8%
Relative Tail Risk	-10.88%

Reward TTM
Sharpe Ratio	2.10
Alpha	69.46
CAGR/Max DD	2.30

Character TTM
Hurst Exponent	0.591
Beta	0.335
Beta Downside	0.308

Drawdowns 3y
Max DD	18.14%
Mean DD	4.53%
Median DD	3.11%

Description: CAH Cardinal Health December 03, 2025

Cardinal Health, Inc. (NYSE:CAH) is a diversified healthcare services and products firm operating in two primary segments: Pharmaceutical & Specialty Solutions and Global Medical Products & Distribution. The company supplies a broad portfolio-including branded and generic drugs, specialty pharmaceuticals, over-the-counter items, and a wide range of medical-surgical devices such as gloves, needles, and procedure kits-to hospitals, health systems, pharmacies, ambulatory surgery centers, labs, physician offices, and home-care patients.

Beyond distribution, Cardinal Health delivers value-added services: specialty drug management for manufacturers, pharmacy-management solutions for hospitals, and repackaging of generics. It also manufactures and distributes its own branded medical products, assembles sterile and non-sterile kits, and produces radiopharmaceuticals, leveraging integrated technology to streamline direct shipments and supply-chain efficiency.

Key performance indicators to watch include FY 2024 revenue growth (≈ $ 3.5 billion YoY increase in the Pharmaceutical segment), operating cash flow (≈ $ 2.2 billion) and the gross margin trend, which reflects pricing pressure from generic competition and rebate dynamics. A critical sector driver is the ongoing shift toward outpatient care and specialty drug utilization, which fuels demand for Cardinal’s specialty-pharmacy services and high-margin medical-device offerings.

For a deeper dive into how Cardinal Health’s supply-chain innovations compare with peers, exploring ValueRay’s analytical platform can provide actionable insights without the fluff.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (1.59b TTM) > 0 and > 6% of Revenue (6% = 14.06b TTM)

FCFTA 0.08 (>2.0%) and ΔFCFTA 5.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -0.74% (prev -0.79%; Δ 0.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.09 (>3.0%) and CFO 5.02b > Net Income 1.59b (YES >=105%, WARN >=100%)

Net Debt (4.44b) to EBITDA (3.26b) ratio: 1.36 <= 3.0 (WARN <= 3.5)

Current Ratio 0.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (239.0m) change vs 12m ago -2.45% (target <= -2.0% for YES)

Gross Margin 3.66% (prev 3.36%; Δ 0.30pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 476.8% (prev 520.9%; Δ -44.11pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 9.21 (EBITDA TTM 3.26b / Interest Expense TTM 263.0m) >= 6 (WARN >= 3)

Altman Z'' 0.26

(A) -0.03 = (Total Current Assets 38.54b - Total Current Liabilities 40.27b) / Total Assets 55.23b

(B) 0.02 = Retained Earnings (Balance) 1.12b / Total Assets 55.23b

(D) 0.06 = Book Value of Equity 3.70b / Total Liabilities 57.96b

Total Rating: 0.26 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 70.33

1. Piotroski 5.0pt

2. FCF Yield 8.36%

3. FCF Margin 1.90%

4. Debt/Equity -3.14

5. Debt/Ebitda 1.36

6. ROIC - WACC (= 28.38)%

7. RoE -55.00%

8. Rev. Trend 88.69%

9. EPS Trend 6.49%

What is the price of CAH shares?

As of January 07, 2026, the stock is trading at USD 208.48 with a total of 1,456,722 shares traded.
Over the past week, the price has changed by +0.86%, over one month by +5.09%, over three months by +34.67% and over the past year by +76.46%.

Is CAH a buy, sell or hold?

Cardinal Health has received a consensus analysts rating of 4.12. Therefore, it is recommended to buy CAH.

Strong Buy: 9
Buy: 2
Hold: 5
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the CAH price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	216.6	3.9%
Analysts Target Price	216.6	3.9%
ValueRay Target Price	304.9	46.2%

CAH Fundamental Data Overview January 03, 2026

Market Cap USD = 48.83b (48.83b USD * 1.0 USD.USD)
P/E Trailing = 30.9488
P/E Forward = 21.097
P/S = 0.2084
P/B = 16.0657
P/EG = 1.9536
Beta = 0.635
Revenue TTM = 234.31b USD
EBIT TTM = 2.42b USD
EBITDA TTM = 3.26b USD
Long Term Debt = 8.98b USD (from longTermDebt, last quarter)
Short Term Debt = 52.0m USD (from shortTermDebt, last quarter)
Debt = 9.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.44b USD (from netDebt column, last quarter)
Enterprise Value = 53.26b USD (48.83b + Debt 9.03b - CCE 4.59b)
Interest Coverage Ratio = 9.21 (Ebit TTM 2.42b / Interest Expense TTM 263.0m)
FCF Yield = 8.36% (FCF TTM 4.45b / Enterprise Value 53.26b)
FCF Margin = 1.90% (FCF TTM 4.45b / Revenue TTM 234.31b)
Net Margin = 0.68% (Net Income TTM 1.59b / Revenue TTM 234.31b)
Gross Margin = 3.66% ((Revenue TTM 234.31b - Cost of Revenue TTM 225.72b) / Revenue TTM)
Gross Margin QoQ = 3.62% (prev 3.66%)
Tobins Q-Ratio = 0.96 (Enterprise Value 53.26b / Total Assets 55.23b)
Interest Expense / Debt = 0.89% (Interest Expense 80.0m / Debt 9.03b)
Taxrate = 24.08% (144.0m / 598.0m)
NOPAT = 1.84b (EBIT 2.42b * (1 - 24.08%))
Current Ratio = 0.96 (Total Current Assets 38.54b / Total Current Liabilities 40.27b)
Debt / Equity = -3.14 (negative equity) (Debt 9.03b / totalStockholderEquity, last quarter -2.88b)
Debt / EBITDA = 1.36 (Net Debt 4.44b / EBITDA 3.26b)
Debt / FCF = 1.00 (Net Debt 4.44b / FCF TTM 4.45b)
Total Stockholder Equity = -2.90b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.89% (Net Income 1.59b / Total Assets 55.23b)
RoE = -55.00% (negative equity) (Net Income TTM 1.59b / Total Stockholder Equity -2.90b)
RoCE = 39.82% (EBIT 2.42b / Capital Employed (Equity -2.90b + L.T.Debt 8.98b))
RoIC = 34.61% (NOPAT 1.84b / Invested Capital 5.31b)
WACC = 6.22% (E(48.83b)/V(57.86b) * Re(7.25%) + D(9.03b)/V(57.86b) * Rd(0.89%) * (1-Tc(0.24)))
Discount Rate = 7.25% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.43%
[DCF Debug] Terminal Value 78.77% ; FCFE base≈3.10b ; Y1≈3.21b ; Y5≈3.64b
Fair Price DCF = 269.1 (DCF Value 63.93b / Shares Outstanding 237.6m; 5y FCF grow 3.48% → 3.0% )
EPS Correlation: 6.49 | EPS CAGR: -44.58% | SUE: -4.0 | # QB: 0
Revenue Correlation: 88.69 | Revenue CAGR: 9.56% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.69 | Chg30d=+0.008 | Revisions Net=-2 | Analysts=15
EPS current Year (2026-06-30): EPS=9.83 | Chg30d=+0.050 | Revisions Net=+15 | Growth EPS=+19.3% | Growth Revenue=+16.1%
EPS next Year (2027-06-30): EPS=11.08 | Chg30d=+0.023 | Revisions Net=+15 | Growth EPS=+12.8% | Growth Revenue=+8.3%

Additional Sources for CAH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle